-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cirtuvivint in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cirtuvivint in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cirtuvivint in Non-Small Cell Lung Cancer Drug Details: SM-08502 is...
-
Product Insights
Tauopathies – Drugs In Development, 2023
Global Markets Direct’s, ‘Tauopathies - Drugs In Development, 2023’, provides an overview of the Tauopathies pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tauopathies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
B-Cell Chronic Lymphocytic Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
B-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cysteamine Hydrochloride in Cystinosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cysteamine Hydrochloride in Cystinosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cysteamine Hydrochloride in CystinosisDrug Details:Cysteamine chlorhydrate/mercaptamine hydrochloride (Cystadrops) is a radiation protective agent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cirtuvivint in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cirtuvivint in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cirtuvivint in Endometrial Cancer Drug Details:SM-08502 is under development for the treatment of...